Drug Profile
AN 215
Alternative Names: AN-215Latest Information Update: 06 Oct 2008
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc; Tulane University School of Medicine; Zentaris
- Developer AEterna Zentaris GmbH; Tulane University School of Medicine
- Class Antineoplastics
- Mechanism of Action DNA intercalators; Gastrin-releasing peptide inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours